β-Galactosidase Gene Transfer to Human Malignant Glioma In Vivo Using Replication-Deficient Retroviruses and Adenoviruses

Abstract

Both retro- and adenovirus-mediated gene therapy have been suggested as a novel approach to the treatment of malignant brain tumors. However, little information is available about the gene transfer efficiency in human malignant glioma in vivo. We compared the feasibility and safety of retrovirus- and adenovirus-mediated beta-galactosidase gene transfer in human malignant glioma. Beta-galactosidase gene was transferred to 10 patients with malignant glioma via a catheter inserted into the tumor. The catheter was left in place until the tumor resection. To maximize gene transfer efficiency, gene transfer vectors (BAG retroviruses, titer, 6 x 10(5) CFU; and adenoviruses, titer from 3 x 10(8) to 3 x 10(10) PFU) were injected into the tumor via the catheter once a day for three consecutive days, followed by tumor resection 1-2 days later. Tumor was resected in such a way that the catheter was still in place inside the tumor, which permitted accurate histological analysis of the transduced tumors. X-Gal staining for beta-galactosidase activity was used to study gene transfer efficiency and distribution of the marker gene. Beta-galactosidase gene transfer was well tolerated with both vectors. Except for two patients with clear increases in serum adenovirus antibody titers, no adverse tissue responses or systemic complications were noticed in any of the patients. Gene transfer was successful in all patients. Gene transfer efficiency varied between <0.01 and 4% with retroviruses and between <0.01 and 11% with adenoviruses. However, the transgene activity was not evenly distributed in the tumors. Both glioma cells and endothelium in the tumor blood vessels were transduced with retro- and adenovirus vectors. In conclusion, the safety and feasibility of in vivo gene transfer to human malignant glioma was established with retro- and adenovirus vectors. Adenoviruses were more efficient than retroviruses in achieving in vivo gene transfer. Transduction of endothelial cells may have important consequences for the proposed treatment strategies and selection of treatment genes. The results justify clinical gene therapy trials for malignant glioma.

Extended release of adenovirus from silica implants in vitro and in vivo

“…In parallel to what is seen in clinical trials featuring intratumoral administration, direct injection resulted in patchy infection of mostly the needle tract. 18 The implant had resorbed completely by day 21. Next, virus release was studied in orthotopic murine tumors, which may be superior over subcutaneous models, as they capture the effect of the tumor environment better.…”

Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice

“…Adenoviruses were analyzed to be free from helper viruses, lipopolysaccharides and bacteriological contaminants. 33,34 Animal model Balb/cA-nu female nude mice (n ¼ 42), 8-10-weeks old, were used for the studies. Ovarian carcinoma was produced by inoculating 1 Â 10 7 SKOV-3m cells into the peritoneal cavity of the nude mice with a 22 G needle.…”

Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer

“…2,9,11 As short-term side effects, they have caused transient inflammatory effects, such as short-term fever, elevation of C-reactive protein (CRP) and formation of anti-adenovirus antibodies. 2,12,13 Liposomes are safe, but their gene transfer efficiency is much lower when compared with that of adenoviruses. The therapeutic effect of non-viral gene transfer is long lasting compared with that of adenoviral gene transfer.…”